Cargando…
4-1BB: A promising target for cancer immunotherapy
Immunotherapy, powered by its relative efficacy and safety, has become a prominent therapeutic strategy utilized in the treatment of a wide range of diseases, including cancer. Within this class of therapeutics, there is a variety of drug types such as immune checkpoint blockade therapies, vaccines,...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515902/ https://www.ncbi.nlm.nih.gov/pubmed/36185242 http://dx.doi.org/10.3389/fonc.2022.968360 |
_version_ | 1784798593777926144 |
---|---|
author | Kim, Alyssa Min Jung Nemeth, Macy Rose Lim, Seung-Oe |
author_facet | Kim, Alyssa Min Jung Nemeth, Macy Rose Lim, Seung-Oe |
author_sort | Kim, Alyssa Min Jung |
collection | PubMed |
description | Immunotherapy, powered by its relative efficacy and safety, has become a prominent therapeutic strategy utilized in the treatment of a wide range of diseases, including cancer. Within this class of therapeutics, there is a variety of drug types such as immune checkpoint blockade therapies, vaccines, and T cell transfer therapies that serve the purpose of harnessing the body’s immune system to combat disease. Of these different types, immune checkpoint blockades that target coinhibitory receptors, which dampen the body’s immune response, have been widely studied and established in clinic. In contrast, however, there remains room for the development and improvement of therapeutics that target costimulatory receptors and enhance the immune response against tumors, one of which being the 4-1BB (CD137/ILA/TNFRSF9) receptor. 4-1BB has been garnering attention as a promising therapeutic target in the setting of cancer, amongst other diseases, due to its broad expression profile and ability to stimulate various signaling pathways involved in the generation of a potent immune response. Since its discovery and demonstration of potential as a clinical target, major progress has been made in the knowledge of 4-1BB and the development of clinical therapeutics that target it. Thus, we seek to summarize and provide a comprehensive update and outlook on those advancements in the context of cancer and immunotherapy. |
format | Online Article Text |
id | pubmed-9515902 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95159022022-09-29 4-1BB: A promising target for cancer immunotherapy Kim, Alyssa Min Jung Nemeth, Macy Rose Lim, Seung-Oe Front Oncol Oncology Immunotherapy, powered by its relative efficacy and safety, has become a prominent therapeutic strategy utilized in the treatment of a wide range of diseases, including cancer. Within this class of therapeutics, there is a variety of drug types such as immune checkpoint blockade therapies, vaccines, and T cell transfer therapies that serve the purpose of harnessing the body’s immune system to combat disease. Of these different types, immune checkpoint blockades that target coinhibitory receptors, which dampen the body’s immune response, have been widely studied and established in clinic. In contrast, however, there remains room for the development and improvement of therapeutics that target costimulatory receptors and enhance the immune response against tumors, one of which being the 4-1BB (CD137/ILA/TNFRSF9) receptor. 4-1BB has been garnering attention as a promising therapeutic target in the setting of cancer, amongst other diseases, due to its broad expression profile and ability to stimulate various signaling pathways involved in the generation of a potent immune response. Since its discovery and demonstration of potential as a clinical target, major progress has been made in the knowledge of 4-1BB and the development of clinical therapeutics that target it. Thus, we seek to summarize and provide a comprehensive update and outlook on those advancements in the context of cancer and immunotherapy. Frontiers Media S.A. 2022-09-14 /pmc/articles/PMC9515902/ /pubmed/36185242 http://dx.doi.org/10.3389/fonc.2022.968360 Text en Copyright © 2022 Kim, Nemeth and Lim https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Kim, Alyssa Min Jung Nemeth, Macy Rose Lim, Seung-Oe 4-1BB: A promising target for cancer immunotherapy |
title | 4-1BB: A promising target for cancer immunotherapy |
title_full | 4-1BB: A promising target for cancer immunotherapy |
title_fullStr | 4-1BB: A promising target for cancer immunotherapy |
title_full_unstemmed | 4-1BB: A promising target for cancer immunotherapy |
title_short | 4-1BB: A promising target for cancer immunotherapy |
title_sort | 4-1bb: a promising target for cancer immunotherapy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515902/ https://www.ncbi.nlm.nih.gov/pubmed/36185242 http://dx.doi.org/10.3389/fonc.2022.968360 |
work_keys_str_mv | AT kimalyssaminjung 41bbapromisingtargetforcancerimmunotherapy AT nemethmacyrose 41bbapromisingtargetforcancerimmunotherapy AT limseungoe 41bbapromisingtargetforcancerimmunotherapy |